Evidence-Based Medicine Guidelines
Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents – assessment of adverse events in non‐randomised studies
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Methylphenidate for Attention Deficit Hyperactivity Disorder (ADHD) in Children and Adolescents – Assessment of Adverse Events in Non‐randomised Studies." Evidence-Based Medicine Guidelines, John Wiley & Sons, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/1305287/all/_________Methylphenidate_for_attention_deficit_hyperactivity_disorder__ADHD__in_children_and_adolescents_–_assessment_of_adverse_events_in_non‐randomised_studies______.
Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents – assessment of adverse events in non‐randomised studies. Evidence-Based Medicine Guidelines. John Wiley & Sons; 2025. https://evidence.unboundmedicine.com/evidence/view/EBMG/1305287/all/_________Methylphenidate_for_attention_deficit_hyperactivity_disorder__ADHD__in_children_and_adolescents_–_assessment_of_adverse_events_in_non‐randomised_studies______. Accessed March 20, 2025.
Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents – assessment of adverse events in non‐randomised studies. (2025). In Evidence-Based Medicine Guidelines. John Wiley & Sons. https://evidence.unboundmedicine.com/evidence/view/EBMG/1305287/all/_________Methylphenidate_for_attention_deficit_hyperactivity_disorder__ADHD__in_children_and_adolescents_–_assessment_of_adverse_events_in_non‐randomised_studies______
Methylphenidate for Attention Deficit Hyperactivity Disorder (ADHD) in Children and Adolescents – Assessment of Adverse Events in Non‐randomised Studies [Internet]. In: Evidence-Based Medicine Guidelines. John Wiley & Sons; 2025. [cited 2025 March 20]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/1305287/all/_________Methylphenidate_for_attention_deficit_hyperactivity_disorder__ADHD__in_children_and_adolescents_–_assessment_of_adverse_events_in_non‐randomised_studies______.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents – assessment of adverse events in non‐randomised studies
ID - 1305287
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/1305287/all/_________Methylphenidate_for_attention_deficit_hyperactivity_disorder__ADHD__in_children_and_adolescents_–_assessment_of_adverse_events_in_non‐randomised_studies______
PB - John Wiley & Sons
DB - Evidence Central
DP - Unbound Medicine
ER -
